Figure 1.

Relative survival of metastatic melanoma patients since first metastasis compared to the background mortality of all Saxon residents (A) depending on the therapy received. The subgroups with certain therapies were exclusive and no other combinations except ICI and TT were displayed. CTx: chemotherapy, ICI: Immune Checkpoint Inhibitor therapy, TT: Targeted therapy, ICI-TT, ICI, and TT in sequential use (order not considered); Relative survival (B) depending on the localization of distant metastases (five common sites and a sixth subgroup with the remaining localizations of metastases) or (C) depending on the time of occurrence of the metastases (synchronous vs. metachronous). (D) Relative survival of the total cohort studied. Risk tables for subgroups and time points (yearwise) were given respectively below each graph. Median survival time for each curve were indicated with a dashed line.